Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group-Reference-Cited by-同舟云学术

Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group

Published:2012-06 Issue:2 Volume:10 Page:99-105
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Liu Glenn,Chen Yu-Hui,DiPaola Robert,Carducci Michael,Wilding George

Funder

National Institutes of Health

U.S. Department of Health and Human Services

National Cancer Institute

U.S. Public Health Service

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference26 articles.

1. Cancer Facts and Figures. 2011;Society,2011

2. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer;Berry;J Urol,2002

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years;Beer;Clin Prostate Cancer,2003

5. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer;Beer;Ann Oncol,2001

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming resistance in prostate cancer with targeted and small molecule-based therapies;Therapy Resistance in Prostate Cancer;2024

2. Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents;Applied Biochemistry and Biotechnology;2022-07-28

3. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer;British Journal of Cancer;2022-02-11

4. Epoxide containing molecules: A good or a bad drug design approach;European Journal of Medicinal Chemistry;2020-09

5. Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio;2019-08-01